GENET-news
To stay informed you can subscribe to the GENET-news list.
2007-05-08 | permalink
Novo Nordisk profits from high GE insulin prices in the U.S.
Insulin analogues sell at a premium over conventional insulin of 5 percent to 10 percent in Japan, 30 percent in Europe, and two to three times as much in the U.S., Jesper Brandgaard, the company’s chief financial officer, said in a telephone interview. The switch to analogues, particularly in the U.S., helped reduce the impact of declining prices for drugs in Europe and Japan, he said.
Overview
News
2007-05-08 | permalink
Novo Nordisk profits from high GE insulin prices in the U.S.
Insulin analogues sell at a premium over conventional insulin of 5 percent to 10 percent in Japan, 30 percent in Europe, and two to three times as much in the U.S., Jesper Brandgaard, the company’s chief financial officer, said in a telephone interview. The switch to analogues, particularly in the U.S., helped reduce the impact of declining prices for drugs in Europe and Japan, he said.
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.